Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/435
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hughes, B. G. M. | en |
dc.contributor.author | Begbie, S. | en |
dc.contributor.author | Muljadi, N. | en |
dc.contributor.author | Davidson, A. | en |
dc.contributor.author | Chan, M. M. K. | en |
dc.contributor.author | Crombie, C. | en |
dc.contributor.author | Briscoe, K. | en |
dc.contributor.author | Broad, A. | en |
dc.contributor.author | Millward, M. | en |
dc.contributor.author | Coskinas, X. | en |
dc.contributor.author | Long, J. | en |
dc.contributor.author | Boyce, A. | en |
dc.contributor.author | Boyer, M. | en |
dc.contributor.author | Varma, S. | en |
dc.contributor.author | Chinchen, S. | en |
dc.contributor.author | Pavlakis, N. | en |
dc.contributor.author | Veillard, A. S. | en |
dc.contributor.author | Tognela, A. | en |
dc.contributor.author | Stockler, M. R. | en |
dc.contributor.author | Lewis, C. R. | en |
dc.contributor.author | Espinoza, D. | en |
dc.contributor.author | Abdi, E. | en |
dc.date.accessioned | 2018-06-16T20:33:54Z | - |
dc.date.available | 2018-06-16T20:33:54Z | - |
dc.date.issued | 2015 | en |
dc.identifier.citation | 26, (11), 2015, p. 2280-2286 | en |
dc.identifier.other | RIS | en |
dc.identifier.uri | http://dora.health.qld.gov.au/qldresearchjspui/handle/1/435 | - |
dc.description.abstract | Background: We sought to determine whether the substantial benefits of topical nitroglycerin with first-line, platinum-based, doublet chemotherapy in advanced nonsmall-cell lung cancer (NSCLC) seen in a phase II trial could be corroborated in a rigorous, multicenter, phase III trial. Patients and methods: Patients starting one of five, prespecified, platinum-based doublets as first-line chemotherapy for advanced NSCLC were randomly allocated treatment with or without nitroglycerin 25 mg patches for 2 days before, the day of, and 2 days after, each chemotherapy infusion. Progression-free survival (PFS) was the primary end point. Results: Accrual was stopped after the first interim analysis of 270 events. Chemotherapy was predominantly with carboplatin and gemcitabine (79%) or carboplatin and paclitaxel (18%). The final analysis included 345 events in 372 participants with a median follow-up of 33 months. Topical nitroglycerin had no demonstrable effect on PFS [median 5.0 versus 4.8 months, hazard ratio (HR) = 1.07, 95% confidence interval (CI) 0.86-1.32, P = 0.55], overall survival (median 11.0 versus 10.3 months, HR = 0.99, 95% CI 0.79-1.24, P = 0.94), or objective tumor response (31% versus 30%, relative risk = 1.03, 95% CI 0.82-1.29, P = 0.81). Headache, hypotension, syncope, diarrhea, dizziness, and anorexia were more frequent in those allocated nitroglycerin. Conclusion: The addition of topical nitroglycerin to carboplatin-based, doublet chemotherapy in NSCLC had no demonstrable benefit and should not be used or pursued further.<br /> | en |
dc.language | en | en |
dc.relation.ispartof | Annals of Oncology | en |
dc.title | A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: The Australasian lung cancer trials group NITRO trial | en |
dc.type | Article | en |
dc.subject.keywords | 12608000588392carboplatin | en |
dc.subject.keywords | cisplatin | en |
dc.subject.keywords | gemcitabine | en |
dc.subject.keywords | glyceryl trinitrate | en |
dc.subject.keywords | lactate dehydrogenase | en |
dc.subject.keywords | navelbine | en |
dc.subject.keywords | paclitaxel | en |
dc.subject.keywords | adult | en |
dc.subject.keywords | advanced cancer | en |
dc.subject.keywords | aged | en |
dc.subject.keywords | anorexia | en |
dc.subject.keywords | article | en |
dc.subject.keywords | cancer combination chemotherapy | en |
dc.subject.keywords | cancer radiotherapy | en |
dc.subject.keywords | cancer staging | en |
dc.subject.keywords | cancer survival | en |
dc.subject.keywords | controlled study | en |
dc.subject.keywords | diarrhea | en |
dc.subject.keywords | dizziness | en |
dc.subject.keywords | drug effect | en |
dc.subject.keywords | drug fatality | en |
dc.subject.keywords | faintness | en |
dc.subject.keywords | female | en |
dc.subject.keywords | follow up | en |
dc.subject.keywords | headache | en |
dc.subject.keywords | histopathology | en |
dc.subject.keywords | human | en |
dc.subject.keywords | hypotension | en |
dc.subject.keywords | male | en |
dc.subject.keywords | medication compliance | en |
dc.subject.keywords | middle aged | en |
dc.subject.keywords | multicenter study | en |
dc.subject.keywords | multiple cycle treatment | en |
dc.subject.keywords | neutrophil count | en |
dc.subject.keywords | neutrophil lymphocyte ratio | en |
dc.subject.keywords | non small cell lung cancer | en |
dc.subject.keywords | objective tumor response | en |
dc.subject.keywords | oncological parameters | en |
dc.subject.keywords | outcome assessment | en |
dc.subject.keywords | overall survival | en |
dc.subject.keywords | patient compliance | en |
dc.subject.keywords | phase 3 clinical trial | en |
dc.subject.keywords | priority journal | en |
dc.subject.keywords | progression free survival | en |
dc.subject.keywords | randomized controlled trial | en |
dc.subject.keywords | survival rate | en |
dc.subject.keywords | survival time | en |
dc.subject.keywords | very elderly | en |
dc.relation.url | http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L607009042http://dx.doi.org/10.1093/annonc/mdv373 | en |
dc.relation.url | http://linksource.ebsco.com/ls.b6e6cc08-c492-42af-aec4-c6084e18e68c.true/linking.aspx?sid=EMBASE&issn=15698041&id=doi:10.1093%2Fannonc%2Fmdv373&atitle=A+phase+III+randomized+trial+of+adding+topical+nitroglycerin+to+first-line+chemotherapy+for+advanced+nonsmall-cell+lung+cancer%3A+The+Australasian+lung+cancer+trials+group+NITRO+trial&stitle=Ann.+Oncol.&title=Annals+of+Oncology&volume=26&issue=11&spage=2280&epage=2286&aulast=Davidson&aufirst=Andrew&auinit=A.&aufull=Davidson+A.&coden=ANONE&isbn=&pages=2280-2286&date=2015&auinit1=A&auinitm= | en |
dc.identifier.risid | 679 | en |
dc.description.pages | 2280-2286 | en |
item.cerifentitytype | Publications | - |
item.openairetype | Article | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
Appears in Sites: | Sunshine Coast HHS Publications |
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.